Gameto Raises $ 23 Million to Redefine Reproductive Longevity with Reprogrammed Ovarian Cells |


NEW YORK, January 10, 2022 / PRNewswire / – Gameto, a biotech startup that solves the problem of accelerated ovarian aging to change the trajectory of women’s health and equality, today announced that it has raised a $ 20 million in a Series A financing led by Future Ventures, with participation from Bold Capital Partners, Lux Capital, Plum Alley, TA Ventures, Overwater Ventures, Robert nelsen and Anne Wojcicki. Gameto also raised $ 3 million In Seed Funding In march 2020 from a range of notable investors, including Jacques Abraham, SALT Fund, FJ Labs, Dan Rose and Brian armstrong.

With some of the initial research carried out at the George Church laboratory in Harvard Medical School, Gameto achieved groundbreaking results by creating the first reprogrammed human ovarian cells (granulosa cells and oocyte precursors) to solve the problem of accelerated ovarian aging, which occurs up to five times faster than it does. any organ in the body.

Gameto builds a platform for ovarian therapy to initially treat menopause and improve assisted fertility with three sequenced programs:

  1. Fertilo – To improve assisted fertility and with the mission of eliminating infertility over time for all women.
  2. Deovo – Initiating Drug Discovery and Computing Platform for Ovarian Aging.
  3. Ameno – Aims to make the medical burden of menopause optional.

Based on the rapidly aging nature of the ovaries, they are an excellent model for studying human aging. Gameto wants to synchronize the rate of ovarian aging with the rate of aging of other organs such as the liver, brain or skin. When the ovaries are referred to as “geriatric” by many traditional medical criteria, the rest of the body certainly is not and this has contributed to the societal and demographic issues we face today. Considering that the lifespan and the lifespan of humans have increased considerably, Gameto believes that this biological phenomenon is no longer suitable for its purpose and that it is a problem that deserves to be addressed. . Gameto sees the potential to expand its platform to the entire aging market.

“The ovaries age five times faster than other organs, resulting in infertility, early menopause and years of increased ill health for women. We want to change the narrative of women’s reproductive longevity and address the root causes of gender inequality in our society. Said Dr. Dina radenkovic, CEO of Gameto.

Dina is a doctor, originally from Serbia, trained in the UK and United States. She worked in the field of aging at the Buck Institute in California, was co-founder and Scientific Director of the Hooke London Longevity Clinic and is a partner of SALT. Gameto also counts Martin Varsavsky as president, Martin is an entrepreneur and, among others, the founder of Prelude Fertility, the largest exclusive network of fertility clinics in United States, and Opening of life, a company working on the automation of the embryology laboratory. Gameto is also part of The Biolabs @ NYULangone program.

Funding for Series A was led by venture capital firm Future Ventures. Founded by Steve Jurvetson and Maryanna saenko, Future Ventures focuses on disruptive, early stage technologies to help pioneering entrepreneurs develop and commercialize unique ideas that have the potential to reinvent industries.

About Gameto:

Situated at New York and Boston, Gameto is a biotechnology company translating the impact of ovarian aging to develop solutions to improve fertility and halt the impact of menopause on female health. Gameto brings together an experienced scientific leadership team with a vision and passion to develop revolutionary platforms for women’s health. Gameto is run by a doctor turned entrepreneur, Dina radenkovic, as CEO and serial entrepreneur and leader in the field of fertility, Martin Varsavsky, as chairman. For more information, visit or contact [email protected]

View original content to download multimedia:



Comments are closed.